Sam Fazeli

That if a phase three has, say, a 60% probability of success when it starts, where would you hope it to be with the application of good AI?

Once you've got to the source.

Yeah, but those statistics are derived from the history of drug development to date.

I mean, I'm not defending and I'm not saying that you won't have a failure.

I have no idea.

But at the end of the day, that's based on what we've been doing so far.

Going forward.

Yes, but Alex, how do you know how much human intervention there was in that AI discovery?

Last question, even though it's paining me that we have to stop here.

I wish I was like, there are podcasts that go on for two or three hours, but I think Alex is going to just turn the camera and the phone off and disappear.

Let's talk about the latest deal you did, which was great timing.

Well, you're doing really well for someone who's dizzy.

Not at all.

It's perfect.

You know, this is not our normal conversation about AI in drug discovery.

So I'm glad you took it slow with us.

But tell us about this latest deal you've done, which of course is with the largest pharma company in the world, one of the largest R&D budgets.

So how long did it take?

And of course, it seems to me that you were pushed or rushed a little bit to get the press release out because of market regulations and rules.

Just talk to us, whatever you can tell us openly about this deal.